Antibody Response to Influenza A(H1N1)pdm09 Among Healthcare Personnel Receiving Trivalent Inactivated Vaccine: Effect of Prior Monovalent Inactivated Vaccine
Antibody Response to Influenza A(H1N1)pdm09 Among Healthcare Personnel Receiving Trivalent Inactivated Vaccine: Effect of Prior Monovalent Inactivated Vaccine
复制标题
DOI：
10.1093/infdis/jit825
复制
发表时间：
2014-06-01
影响因子：
6.4
通讯作者：
Thompson, Mark
中科院分区：
文献类型：
--
作者：
Gaglani, Manjusha;Spencer, Sarah;Thompson, Mark
背景。关于每年重复注射甲型 H1N1 流感 pdm09 疫苗的免疫原性数据很少。方法.a欧洲积分 2010 年秋季，我们在 2 个自愿免疫中心招募了医护人员 (HCP) 参与直接患者护理。我们核实了含有 A(H1N1)pdm09 的单价灭活流感疫苗 (MIIV) 和 2010-2011 年三价灭活流感疫苗 (TIV) 的收据。我们对季前、TIV 后和季末血清样本进行了血凝抑制抗体 (HI) 测定。我们将每份收到上赛季 MIIV、本赛季 TIV、两者或两者都接受的 HI 滴度为千分之 40 的 HCP 比例与 A(H1N1)pdm09 进行了比较。结果.a欧元积分 在季前赛 (n = 1417)，接受 MIIV 的人 (34%) 与未接受 MIIV 的人 (14%) 相比，HI 滴度为千分之 40 的 HCP 明显更高（调整后的相对风险 [ARR]， 3.26；95% 置信区间 [CI]，2.72-3.81）。在 TIV 后 (n = 865)，接受 MIIV 和 TIV 的 HCP (66%) 中的 HI (千分之 40) 低于仅接受 TIV 的患者 (85%) (ARR，0.93 [95% CI，0.84-.997])。在季末 (n = 1254)，HI a 千分之 40 在同时接受 MIIV 和 TIV 的人中为 40%，在仅接受 TIV 的人中为 67% (ARR, 0.76 [95% CI, .65-.88])，在仅接受 MIIV 的人中为 52%，在未接受 MIIV 的人中为 12%。 结论.aEuro 整体 HCP 免疫计划应考虑效果宿主免疫反应和疫苗抗原距离对每年重复剂量流感疫苗免疫原性的影响。
Background. Few data are available on the immunogenicity of repeated annual doses of influenza A(H1N1) pdm09-containing vaccines.Methods.aEuro integral We enrolled healthcare personnel (HCP) in direct patient care during the autumn of 2010 at 2 centers with voluntary immunization. We verified the receipt of A(H1N1)pdm09-containing monovalent inactivated influenza vaccine (MIIV) and 2010-2011 trivalent inactivated vaccine (TIV). We performed hemagglutination inhibition antibody (HI) assays on preseason, post-TIV, and end-of-season serum samples. We compared the proportion of HCPs with HI titer a parts per thousand yen40 against A(H1N1)pdm09 per receipt of prior-season MIIV, current-season TIV, both, or neither.Results.aEuro integral At preseason (n = 1417), HI a parts per thousand yen 40 was significantly higher among those who received MIIV (34%) vs those who did not (14%) (adjusted relative risk [ARR], 3.26; 95% confidence interval [CI], 2.72-3.81). At post-TIV (n = 865), HI a parts per thousand yen 40 was lower among HCP who received MIIV and TIV (66%) than among those receiving only TIV (85%) (ARR, 0.93 [95% CI, .84-.997]). At end-of-season (n = 1254), HI a parts per thousand yen 40 was 40% among those who received both MIIV and TIV and 67% among those receiving only TIV (ARR, 0.76 [95% CI, .65-.88]), 52% among those who received MIIV only, and 12% among those receiving neither.Conclusions.aEuro integral HCP immunization programs should consider effects of host immune response and vaccine antigenic distance on immunogenicity of repeated annual doses of influenza vaccines.